Amgen (NASDAQ:AMGN) Shares Unloaded Rep. David Taylor

Representative David Taylor (Republican-Ohio) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on March 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in Amgen stock on February 26th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Fifth Third Bancorp (NASDAQ:FITB) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Parker-Hannifin (NYSE:PH) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 2/26/2026.
• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Marathon Petroleum (NYSE:MPC) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Kroger (NYSE:KR) on 2/26/2026.
• Sold $15,001 – $50,000 in shares of International Business Machines (NYSE:IBM) on 2/26/2026.
• Sold $15,001 – $50,000 in shares of Salesforce (NYSE:CRM) on 2/26/2026.

Amgen Trading Down 0.2%

Shares of AMGN traded down $0.73 during mid-day trading on Tuesday, reaching $376.24. The stock had a trading volume of 306,149 shares, compared to its average volume of 2,798,501. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The firm has a market cap of $202.82 billion, a price-to-earnings ratio of 26.41, a P/E/G ratio of 3.67 and a beta of 0.45. The business’s fifty day moving average is $354.21 and its 200 day moving average is $323.38. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the previous year, the business earned $5.31 earnings per share. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

Institutional Trading of Amgen

A number of hedge funds have recently added to or reduced their stakes in AMGN. Corient Private Wealth LLC lifted its holdings in Amgen by 54.0% in the fourth quarter. Corient Private Wealth LLC now owns 537,630 shares of the medical research company’s stock valued at $176,000,000 after acquiring an additional 188,531 shares during the period. Union Savings Bank purchased a new position in Amgen in the fourth quarter valued at about $418,000. Hsbc Holdings PLC boosted its stake in shares of Amgen by 7.7% during the 4th quarter. Hsbc Holdings PLC now owns 1,537,251 shares of the medical research company’s stock worth $503,570,000 after acquiring an additional 110,357 shares in the last quarter. Worthington Financial Partners LLC purchased a new position in Amgen in the 4th quarter valued at approximately $299,000. Finally, Bayban purchased a new stake in Amgen during the fourth quarter worth $206,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

AMGN has been the subject of several recent research reports. Barclays initiated coverage on shares of Amgen in a research note on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price objective for the company. Scotiabank initiated coverage on Amgen in a report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price target on the stock. HSBC reaffirmed a “buy” rating and issued a $425.00 target price on shares of Amgen in a report on Wednesday, December 10th. Guggenheim lifted their price objective on shares of Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Finally, Argus upped their price objective on Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and a consensus price target of $354.00.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.